Catalent secures further Covid-19 vaccine business with AstraZeneca
Catalent is to provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222.
Archives for September 1, 2020
FDA tees up pre-election deep dive into COVID-19 vaccines
FDA schedules COVID-19-focused vaccine advisory committee for 12 days before US presidential election.
Failure of ex-US Kevzara phase 3 further dents IL-6 COVID-19 hypothesis
Sanofi’s Kevzara fails to beat placebo in COVID-19 phase 3, further diminishing hopes of repurposing anti-IL-6 antibodies.
Australia tracks 35% jump in flu vaccine shipments
Flu vaccine shipments surge to record high in Australia against backdrop of COVID-19 pandemic.
Nestlé to acquire Aimmune Therapeutics, growing food allergy portfolio
Swiss giant Nestlé is to acquire Aimmune Therapeutics, a biopharmaceutical company developing and commercializing treatments for food allergies. Aimmune’s Palforzia is the world’s first approved treatment for peanut allergy.